Potential predictors of survival after surgery for colorectal cancer patients with synchronous unresectable liver metastases

Oncology Reports

Volumn 16, Issue 6, 2006, Pages 1369-1374

  Hotta, Tsukasa ^a   Takifuji, Katsunari ^a   Uchiyama, Kazuhisa ^a   Yokoyama, Shozo ^a   Matsuda, Kenji ^a   Higashiguchi, Takashi ^a   Tominaga, Toshiji ^a   Oku, Yoshimasa ^a   Nasu, Toru ^a   Yamaue, Hiroki ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Colorectal cancer; Liver metastasis; Prognostic factor

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD; COLORECTAL TUMOR; FEMALE; HUMAN; LIVER TUMOR; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RISK FACTOR; SURVIVAL;

ADENOCARCINOMA; AGED; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 39049186022     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.6.1369     Document Type: Article

References (35)

1. Le Voyer TE, Sigurdson ER, Hanlon AL, et al: Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 21: 2912-2919, 2003. (Pubitemid 46621841)
2. Hotta T, Takifuji K, Arii K, Yokoyama S, Matsuda K, Higashiguchi T, Tominaga T, Oku Y and Yamaue H: Toxicity during l-LV/5FU adjuvant chemotherapy as a modified RPMI regimen for patients with colorectal cancer. Oncol Rep 14: 433-439, 2005.
3. Stangl R, Altendolf-Hofmann A, Charnley RM, et al: Factors influencing the natural history of colorectal liver metastases. Lancet 343: 1405-1410, 1994. (Pubitemid 24167517)
4. Adam R, Delvart V, Pascal G, et al: Rescue survey for unresectable colorectal liver metastases downstaged by chemotherapy. A model to predict long-term survival. Ann Surg 240: 644-658, 2004. (Pubitemid 39281287)
5. Scheele J, Stang R, Altendorf-Hofmann A and Paul M: Resection of colorectal liver metastases. World J Surg 19: 59-71, 1995.
6. Rodgers MS and NcCall JL: Surgery for colorectal liver metastases with hepatic lymph node involvement: a systematic review. Br J Surg 87: 1142-1155, 2000.
7. Jaeck D, Oussoultzoglou E, Rosso E, Greget M, Weber JC and Bachellier P: A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilober colorectal liver metastases. Ann Surg 240: 1037-1051, 2004. (Pubitemid 39602131)
8. Cady B, Stone MD and McDermott W: Technical and biological factors in disease-free survival after hepatic resection for colorectal cancer metastases. Arch Surg 127: 561-569, 1992.
9. UICC: TNM classification of malignant tumors. 4th edition. Berlin Heidelberg, Springer-Verlag, New York, 1997.
10. Japanese Society for Cancer of the Colon and Rectum: Japanese classification of colorectal carcinoma. 1st English edition. Kanehara Co., Ltd., Tokyo, 1997.
11. Petrelli N, Douglass HO, Herrera L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 7: 1419-1426, 1989. (Pubitemid 19245111)
12. Petrelli N, Herrera L and Rustum Y, et al: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5: 1559-1565, 1987. (Pubitemid 18010132)
13. Dhar DK, Yoshimura H, Kinukawa N, et al: Metastatic lymph node size and colorectal cancer prognosis. J Am Coll Surg 200: 20-28, 2005. (Pubitemid 41583111)
14. Jaeck D, Bachellier P, Guiguet M, et al: Long-term survival following resection of colorectal hepatic metastases. Br J Surg 84: 977-980, 1997. (Pubitemid 27310867)
15. Fong Y, Cohen AM, Fortner JG, et al: Liver resection for colorectal metastases. J Clin Oncol 15: 938-946, 1997. (Pubitemid 27106275)
16. Nordlinger B, Guiguet M, Vaillant JC, et al: Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Cancer 77: 1254-1262, 1996. (Pubitemid 26102322)
17. Minagawa M, Makuuchi M, Torzilli G, et al: Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer. Long-term results. Ann Surg 231: 487-499, 2000. (Pubitemid 30185854)
18. Okano K, Yamamoto J, Moriya Y, et al: Macroscopic intrabiliary growth of liver metastases from colorectal cancer. Surgery 126: 829-834, 1999. (Pubitemid 29523320)
19. Yasui K, Hirai T, Kato T, et al: A new macroscopic classification predicts prognosis for patient with liver metastases from colorectal cancer. Ann Surg 226: 582-586, 1997. (Pubitemid 28049653)
20. Ambiru S, Miyazaki M, Isono T, et al: Hepatic resection for colorectal metastases. Analysis of prognostic factors. Dis Colon Rectum 42: 632-639, 1999. (Pubitemid 29228409)
21. Lunevicius R, Nakanishi H, Ito S, et al: Clinicopathological significance of fibrotic capsule formation around liver metastasis from colorectal cancer. J Cancer Res Clin Oncol 127: 193-199, 2001. (Pubitemid 32449071)
22. Koike M, Yasui K, Torii A, et al: Prognostic significance of entrapped liver cells in hepatic metastases from colorectal cancer. Ann Surg 232: 653-657, 2000.
23. Fong Y, Fortner J, Ba RLS, Brennan MF and Blumgart LH: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Analysis of 1001 consecutive cases. Ann Surg 230: 309-321, 1999. (Pubitemid 30191861)
24. Hohenberger P, Schlag PM, Gerneth T and Herfarth C: Pre- and postoperative carcinoembryonic antigen determinations in hepatic resection for colorectal metastases. Ann Surg 219: 135-143, 1994.
25. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343: 905-914, 2000.
26. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047, 2000. (Pubitemid 30162806)
27. De Gramont A, Vignoud J, Tournigand C, et al: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-h continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33: 214-219, 1997.
28. Poston GJ: The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. Eur J Surg Oncol 31: 325-330, 2005.
29. Martin JK Jr, O'Connell MJ, Wieand HS, et al: Intra-arterial floxuridine vs. systemic fluorouracil for hepatic metastases from colorectal cancer: a randomized trial. Arch Surg 125: 1022-1027, 1990. (Pubitemid 20249340)
30. Kemeny N, Gonen M, Sullivan D, et al: Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 19: 2687-2695, 2001. (Pubitemid 32441374)
31. Kemeny N, Huang Y, Cohen AM, et al: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341: 2039-2048, 1999. (Pubitemid 30035952)
32. Lorenz M, Muller HH, Schramm H, et al: Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. Ann Surg 228: 756-762, 1998. (Pubitemid 30191686)
33. Bismuth H, Adam R, Lévi F, et al: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224: 509-522, 1996. (Pubitemid 26337559)
34. Adam R, Laurent A, Azoulay D, Castaing D and Bismuth H: Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg 232: 777-785, 2000.
35. Shimada H, Tanaka K, Masui H, et al: Results of surgical treatment for multiple (≥5 nodules) bi-lobar hepatic metastases from colorectal cancer. Langenbecks Arch Surg 389: 114-121, 2004. (Pubitemid 38660681)